Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12225558 | 0.96 | KIF11 (1.00) | KIF11 | |
| SCHEMBL12225499 | 0.95 | KIF11 (0.91) | KIF11 | |
| SCHEMBL12225502 | 0.91 | KIF11 (0.91) | KIF11 | |
| SCHEMBL76162 | 0.89 | KIF11 (0.88) | KIF11 | |
| SCHEMBL74610 | 0.89 | KIF11 (0.88) | KIF11 | |
| SCHEMBL76163 | 0.89 | KIF11 (0.88) | KIF11 | |
| SCHEMBL74609 | 0.89 | KIF11 (0.88) | KIF11 | |
| SCHEMBL77150 | 0.89 | KIF11 (0.88) | KIF11 | |
| SCHEMBL74019 | 0.89 | KIF11 (0.80) | KIF11 | |
| SCHEMBL75785 | 0.89 | KIF11 (0.80) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140056880-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-20140056880-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2014-02-27 | — | — | US | disclosed |
| US-8546434-B2 | Triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| US-8546434-B2 | Triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| WO-2011128381-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110256128-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110256128-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110256128-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP17A1, CYP51A1, KLKB1 | KIF11 101/4885 |
| US-20140056880-A1 | TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP17A1, CYP51A1, KLKB1 | KIF11 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.